CD44-targeted nanoparticles with GSH-responsive activity as powerful therapeutic agents against breast cancer
Copyright © 2022 Elsevier B.V. All rights reserved..
DOX-loaded nanoparticles able to actively target CD44-receptors and respond to redox stimuli were proposed as non-conventional chemotherapeutic strategy in breast cancer. A covalent conjugate of human serum albumin and hyaluronic acid was prepared and assembled by a GSH-mediated desolvation in disulfide-crosslinked solid nanoparticles with mean diameter of 120 nm ± 3.4. The effective internalization of nanoparticles in cancer cells via CD44-receptors, together with the more efficient intracellular release, resulted in a significant increase of drug efficacy, with IC50 reduced from 0.9959 and 2.516 μg mL-1 to 0.4014 and 0.3094 μg mL-1 for MCF-7 and MDA-MB-231, respectively. Conversely, no enhancement in drug toxicity was recorded in healthy MCF-10A cells. The efficacy of the proposed formulation was further investigated in the different biological steps involved in metastasis process, paving the way for further in vivo experiments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:221 |
|---|---|
| Enthalten in: |
International journal of biological macromolecules - 221(2022) vom: 30. Nov., Seite 1491-1503 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Brindisi, Matteo [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 02.11.2022 Date Revised 02.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijbiomac.2022.09.157 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346470641 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346470641 | ||
| 003 | DE-627 | ||
| 005 | 20231226031534.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijbiomac.2022.09.157 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346470641 | ||
| 035 | |a (NLM)36130642 | ||
| 035 | |a (PII)S0141-8130(22)02088-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Brindisi, Matteo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CD44-targeted nanoparticles with GSH-responsive activity as powerful therapeutic agents against breast cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.11.2022 | ||
| 500 | |a Date Revised 02.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
| 520 | |a DOX-loaded nanoparticles able to actively target CD44-receptors and respond to redox stimuli were proposed as non-conventional chemotherapeutic strategy in breast cancer. A covalent conjugate of human serum albumin and hyaluronic acid was prepared and assembled by a GSH-mediated desolvation in disulfide-crosslinked solid nanoparticles with mean diameter of 120 nm ± 3.4. The effective internalization of nanoparticles in cancer cells via CD44-receptors, together with the more efficient intracellular release, resulted in a significant increase of drug efficacy, with IC50 reduced from 0.9959 and 2.516 μg mL-1 to 0.4014 and 0.3094 μg mL-1 for MCF-7 and MDA-MB-231, respectively. Conversely, no enhancement in drug toxicity was recorded in healthy MCF-10A cells. The efficacy of the proposed formulation was further investigated in the different biological steps involved in metastasis process, paving the way for further in vivo experiments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a CD44 receptors | |
| 650 | 4 | |a GSH-responsive | |
| 650 | 4 | |a HA-HSA conjugate | |
| 650 | 4 | |a Metastasis process | |
| 650 | 4 | |a Targeted nanoparticles | |
| 650 | 7 | |a Hyaluronic Acid |2 NLM | |
| 650 | 7 | |a 9004-61-9 |2 NLM | |
| 650 | 7 | |a Doxorubicin |2 NLM | |
| 650 | 7 | |a 80168379AG |2 NLM | |
| 650 | 7 | |a CD44 protein, human |2 NLM | |
| 650 | 7 | |a Hyaluronan Receptors |2 NLM | |
| 700 | 1 | |a Curcio, Manuela |e verfasserin |4 aut | |
| 700 | 1 | |a Frattaruolo, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Cirillo, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Leggio, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Rago, Vittoria |e verfasserin |4 aut | |
| 700 | 1 | |a Nicoletta, Fiore Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Cappello, Anna Rita |e verfasserin |4 aut | |
| 700 | 1 | |a Iemma, Francesca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of biological macromolecules |d 1992 |g 221(2022) vom: 30. Nov., Seite 1491-1503 |w (DE-627)NLM012627356 |x 1879-0003 |7 nnns |
| 773 | 1 | 8 | |g volume:221 |g year:2022 |g day:30 |g month:11 |g pages:1491-1503 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijbiomac.2022.09.157 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 221 |j 2022 |b 30 |c 11 |h 1491-1503 | ||